Novartis Projects OTC Return By Summer, Expects Flat Sales In 2012
This article was originally published in The Tan Sheet
Executive Summary
Novartis’ 2012 guidance conservatively assumes the offline OTC facility in Lincoln, Neb., will return to production by mid-year, CEO Joseph Jimenez says. The firm halted shipments of Excedrin and other OTCs from Lincoln in December, and consumer health sales fell 7.3% in the fourth quarter.